COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients
Article 2023 en
Authors
AB
Alvino Bisecco
FM
Federica Matrone
MC
Marco Capobianco
Abstract
1 min read
Despite the significant extension of OCR infusion interval during the first wave of pandemic in Italy, a very small incidence of clinical/radiological events was observed, thus suggesting durable efficacy of OCR, as well as the absence of rebound after its short-term suspension.
Sven Schippling, Jeffrey A. Cohen, Alasdair Coles, D. A. S. Compston, Edward Fox, Massimo Filippi, Hans‐Peter Hartung, Eva Havrdová, Krzysztof Selmaj, Frederik Barkhof, David Margolin, Karthinathan Thangavelu, Douglas L. Arnold
Discussion(0)
No comments yet. Be the first to comment.